US FDA Puts Compounding Office Under CDER Compliance To 'Institutionalize' Maturing Program

The US FDA plans to give its young drug compounding oversight program new leadership and move it from the drug center director's office down to the center's compliance office. Whether this move translates into heightened enforcement of drug compounders remains to be seen.